


**SUPPLEMENTAL FIGURE 1**

<sup>89</sup>Zr-bevacizumab healthy tissue uptake of all patients. All 14 patients underwent <sup>89</sup>Zr-bevacizumab PET at both baseline and 2 weeks (spleen uptake n = 11; three patients had splenectomy). Ten of these 14 patients also underwent <sup>89</sup>Zr-bevacizumab PET at 12 weeks (spleen uptake n = 8). Median and interquartile range are given.



**SUPPLEMENTAL FIGURE 2**

Each patient is represented by a separate color. A, per patient values are given of the most intense tumor lesion visualized at baseline scan.  $SUV_{max}$  values are shown at baseline, 2 weeks and 12 weeks. B, shows the percentage change in  $SUV_{max}$  of the most intense tumor

lesion at baseline scan. C–H, shows tumor uptake in patients in which  $^{89}\text{Zr}$ -bevacizumab PET visualized more than 1 tumor lesion. For most patients, the tracer uptake in tumor lesions shows the same direction of change in  $\text{SUV}_{\text{max}}$  after 2 and 12 weeks.